Tekmira Pharma in Focus as the World Awaits Ebola Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 5:34PM CDT
Tekmira (TKMR) is in focus following Ebola outbreak.
Nasdaq stocks posting largest volume increases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage decreases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Today's Dead Cat Bounce Stock Is Tekmira Pharmaceuticals (TKMR)
at The Street - Tue Aug 05, 9:01AM CDT
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a "dead cat bounce" (down big yesterday but up big today) candidate
'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.
Why Tekmira Pharmaceuticals (TKMR) Stock Is Spiking Today
at The Street - Mon Aug 04, 9:24AM CDT
Tekmira Pharmaceuticals (TKMR) shares are gaining following reports that the FDA could reconsider its Ebola treatment as the outbreak of the disease worsens in Africa.
The Tekmira Ebola Trade May Already Be Over
at The Street - Mon Aug 04, 9:07AM CDT
CNN reports competing, secret Ebola therapy already saved lives of U.S. aid workers.
Tekmira Provides Update on TKM-Ebola Phase I Clinical Hold
GlobeNewswire - Mon Jul 21, 11:19AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced an update on the TKM-Ebola Phase I clinical hold. The Company has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) and is preparing a Complete Response to the Agency. The Company anticipates this matter will be resolved by Q4, 2014.
Tekmira Receives $1.5 Million Milestone Payment
GlobeNewswire - Wed Jul 09, 6:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has received a $1.5 million milestone payment from Monsanto following completion of specified program developments. The development milestone is part of the research program under the Option Agreement Tekmira signed with the agriculture company, which we announced on January 13, 2014. The Option Agreement relates to Tekmira's proprietary delivery technology and intellectual property for use in agricultural applications. The potential value of the transaction could reach up to $86.2 million, following the successful completion of all program milestones.
Why Tekmira Pharmaceuticals (TKMR) Stock Is Plunging Today
at The Street - Thu Jul 03, 10:59AM CDT
Tekmira Pharmaceuticals (TKMR) plunged Thursday after the company announced it had received verbal notice from the FDA of a clinical hold on the company's TKM-Ebola Phase I clinical trial.
Tekmira Receives Notice of Clinical Hold for TKM-Ebola Phase I Clinical Trial
GlobeNewswire - Thu Jul 03, 2:15AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has received verbal notice from the U. S. Food and Drug Administration (FDA) that the TKM-Ebola Phase I healthy volunteer clinical study has been placed on clinical hold. This notice applies only to this study.
Ebola Viral Infections - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nmqftt/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Tekmira Pharmaceuticals Corp. - Toyama Chemical Co., Ltd. - Medicago Inc. - Zalicus Inc. - Summit Corporation plc - Vaxart, Inc. - Navigen Pharmaceuticals, Inc. - Humabs BioMed SA For more information visit http://www.researchandmarkets.com/research/nm...bola_viral